» Articles » PMID: 39452435

Synergistic Effect of Metronidazole and Chlorhexidine Against Growth: An In Vitro Study

Overview
Journal Dent J (Basel)
Specialty Dentistry
Date 2024 Oct 25
PMID 39452435
Authors
Affiliations
Soon will be listed here.
Abstract

To evaluate the potential synergistic activity of metronidazole (MTZ) and chlorhexidine (CHX) against growth. Antimicrobial susceptibility tests of to MTZ and CHX were performed on in vitro serial 2-fold dilutions of MTZ (from 1 mg/mL to 0.015 mg/mL) and CHX (from 1 mg/mL to 0.03 mg/mL) in thioglycollate medium broth in a 96-well plate. The turbidity of each sample was analyzed by absorbance spectrophotometry at 450 nm wavelengths by using an enzyme-linked immunosorbent assay (ELISA) reader. The MIC50 (minimum inhibitory concentration) and MBC (minimum bactericidal concentration) were assessed. To investigate the potential synergism between MTZ and CHX, bacterial cells were treated with MTZ or CHX, as described above, either alone or in combination. The MIC of MTZ was 0.03 mg/mL while that of CHX ranged from 0.12 to 0.06 mg/mL. MTZ and CHX exerted a significant inhibitory effect on growth in a dose-dependent manner. MTZ at a low and ineffective concentration of 0.015 mg/mL, associated with a suboptimal concentration of CHX (0.03 mg/mL), exhibited a significant synergistic inhibitory effect on bacterial growth (50% inhibition vs. control) ( < 0.001), and the effect was more remarkable with 0.06 mg/mL CHX (75% inhibition vs. control). CHX and MTZ showed a significant synergistic effect against growth. A non-effective concentration of MTZ (0.015 mg/mL) combined with suboptimal concentrations of CHX (0.03 mg/mL and 0.06 mg/mL) were related to a 50% growth in the inhibition and 99.99% death of , respectively. The applicability of the clinical use of these concentrations should be tested in randomized controlled trials.

Citing Articles

Antimicrobial activity of L. Pers against periodontal pathogen: .

Bakri H, Syed Abdul Rahman S, Dol Bakri Z, Munadziroh E, Wan Harun W PeerJ. 2024; 12:e18751.

PMID: 39713137 PMC: 11662893. DOI: 10.7717/peerj.18751.

References
1.
Sanz M, Marco Del Castillo A, Jepsen S, Gonzalez-Juanatey J, DAiuto F, Bouchard P . Periodontitis and cardiovascular diseases: Consensus report. J Clin Periodontol. 2020; 47(3):268-288. PMC: 7027895. DOI: 10.1111/jcpe.13189. View

2.
Szulc M, Zakrzewska A, Zborowski J . Local drug delivery in periodontitis treatment: A review of contemporary literature. Dent Med Probl. 2018; 55(3):333-342. DOI: 10.17219/dmp/94890. View

3.
Cosgarea R, Jepsen S, Heumann C, Batori-Andronescu I, Rosu A, Bora R . Clinical, microbiological, and immunological effects of 3- or 7-day systemic antibiotics adjunctive to subgingival instrumentation in patients with aggressive (Stage III/IV Grade C) periodontitis: A randomized placebo-controlled clinical trial. J Clin Periodontol. 2022; 49(11):1106-1120. DOI: 10.1111/jcpe.13676. View

4.
Basudan A . Nanoparticle based periodontal drug delivery - A review on current trends and future perspectives. Saudi Dent J. 2022; 34(8):669-680. PMC: 9767828. DOI: 10.1016/j.sdentj.2022.09.006. View

5.
Mauri-Obradors E, Merlos A, Estrugo-Devesa A, Jane-Salas E, Lopez-Lopez J, Vinas M . Benefits of non-surgical periodontal treatment in patients with type 2 diabetes mellitus and chronic periodontitis: A randomized controlled trial. J Clin Periodontol. 2017; 45(3):345-353. DOI: 10.1111/jcpe.12858. View